Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate)

Annals of the Rheumatic Diseases

Volumn 77, Issue 2, 2018, Pages 212-220

  Khanna, Dinesh ^a   Denton, Christopher P ^b   Lin, Celia J F ^c   Van Laar, Jacob M ^d   Frech, Tracy M ^e   Anderson, Marina E ^f   Baron, Murray ^g   Chung, Lorinda ^h   Fierlbeck, Gerhard ⁱ   Lakshminarayanan, Santhanam ^j   Allanore, Yannick ^k   Pope, Janet E ^l   Riemekasten, Gabriela ^m   Steen, Virginia ⁿ   Müller Ladner, Ulf ^o   Spotswood, Helen ^p   Burke, Laura ^p   Siegel, Jeffrey ^c   Jahreis, Angelika ^c   Furst, Daniel E ^q  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GENENTECH INC   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g MCGILL UNIVERSITY   (Canada)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l WESTERN UNIVERSITY   (Canada)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ GEORGETOWN UNIVERSITY   (United States)

^o JUSTUS LIEBIG UNIVERSITY   (Germany)

^p ROCHE PRODUCTS LTD   (United Kingdom)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMYELINATION; DESCRIPTIVE RESEARCH; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED VITAL CAPACITY; HUMAN; INFECTION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MODIFIED RODNAN SKIN SCORE; MULTICENTER STUDY; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYSTEMIC SCLEROSIS; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85041502058     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211682     Document Type: Article

References (40)

1. Nikpour M, Stevens WM, Herrick AL, et al. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 2010;24:857-69.
2. Denton CP. Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 2015;33(4 Suppl 92):S3-7.
3. Denton CP, Khanna D. Systemic sclerosis. The Lancet 2017;S0140-6736(17)30933-9. [Epub ahead of print].
4. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
5. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
6. Khanna D, Distler JHW, Sandner P, et al. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord 2016;1:186-93.
7. Muangchant C, Pope JE. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 2013;31(2 Suppl 76):122-34.
8. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012;39:1120-4.
9. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61:239-46.
10. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012;71:1235-42.
11. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40:435-46.
12. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
13. Matsushita T, Hasegawa M, Hamaguchi Y, et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006;33:275-84.
14. Muangchan C, Harding S, Khimdas S, et al. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res 2012;64:1405-14.
15. Genentech Inc. Actemra (tocilizumab) injection for intravenous infusion. South San Francisco,CA: Genentech, Inc, 2017.
16. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010;49:2408-12.
17. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217-20.
18. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630-40.
19. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
20. Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325-9.
21. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case ofbinomial. Biometrika 1934;26:404-13.
22. Distler O, Distler JH. Tocilizumab for systemic sclerosis: implications for future trials. Lancet 2016;387:2580-1.
23. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
24. Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768-80.
25. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
26. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003-9.
27. Foocharoen C, Siriphannon Y, Mahakkanukrauh A, et al. Incidence rate and causes of infection in Thai systemic sclerosis patients. Int J Rheum Dis 2012;15:277-83.
28. Muangchan C, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. a systematic review. J Rheumatol 2013;40:1545-56.
29. Buch MH, Aletaha D, Emery P, et al. Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 2011;70:886-90.
30. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
31. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology 2015;54:1944-53.
32. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
33. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
34. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stemcell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
35. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-8.
36. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100:1602-10.
37. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
38. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
39. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-19.
40. Namas R, Tashkin DP, Furst DE, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: Post-hoc analyses from the Scleroderma Lung Study I and II. Arthritis Care Res 2017.